Waibel, Brian J.,Schonemann, Hans,Krukonis, Val,Kagan, Michael
申请号：
NZ70908313
公开号：
NZ709083A
申请日:
2013.12.18
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
The invention provides an EPA composition comprising: from 15 wt. % to 90 wt. % eicosapentaenoic acid (EPA) and 10 wt. % to 70 wt. % polar lipids, wherein the polar lipids comprise phospholipid conjugates and glycolipid conjugates, 5 wt. % to 50 wt. % of the EPA in the composition is a glycolipid conjugate, 3 wt. % to 50 wt. % of the EPA in the composition is a phospholipid conjugate, and 0 wt. % to 10 wt. % of the EPA in the composition is a triglyceride conjugate or a diglyceride conjugate, and wherein the composition comprises less than 5 wt. % esterified EPA, does not comprise docosahexaenoic acid (DHA), and wherein the composition is suitable for human consumption. The invention also provides an EPA composition comprising the following distribution of EPA by lipid class: 3 wt. % to 50 wt. % of the EPA is a phospholipid conjugate； 5 wt. % to 50 wt. % of the EPA is a glycolipid conjugate； 0 wt. % to 10 wt. % of the EPA is a triglyceride conjugate or a diglyceride conjugate； and 15 wt. % to 85 wt. % of the EPA is in free fatty acid form, wherein the composition is suitable for human consumption. The invention also provides methods of producing an EPA composition of this invention.
